Abstract
Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Current Medicinal Chemistry
Title:Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy
Volume: 21 Issue: 21
Author(s): H. Li and W. Ma
Affiliation:
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Abstract: Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Export Options
About this article
Cite this article as:
Li H. and Ma W., Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy, Current Medicinal Chemistry 2014; 21 (21) . https://dx.doi.org/10.2174/092986732121140521100224
DOI https://dx.doi.org/10.2174/092986732121140521100224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Germline Genetics of the p53 Pathway Affect Longevity in a Gender Specific Manner
Current Aging Science MRI of Focal Liver Lesions
Current Medical Imaging Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry Current and Future Directions in the Treatment of Metastatic Malignant Melanoma
Current Medicinal Chemistry - Anti-Cancer Agents Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins
Current Organic Chemistry The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design <i>In Vitro</i> Validation of Camphene as a Potential Antiviral Agent Against Betanodavirus Causing Viral Nervous Necrosis in Barramundi
Anti-Infective Agents Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Plant Natural Products in Anticancer Drug Discovery
Current Organic Chemistry LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina?
Current Neuropharmacology